Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments

References

• Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol. 2003;170(1):5–11.
   PubMed Web of Science ®Google Scholar
• Hanna NH, Einhorn LH. Testicular cancer–discoveries and updates. N Engl J Med. 2014;371(21):2005–2016.
   PubMed Web of Science ®Google Scholar
• Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32(28):3085–3092.
   PubMed Web of Science ®Google Scholar
• (IGCCCG) IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594–603.
   PubMed Web of Science ®Google Scholar
• Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol. 2015;68(6):1054–1068.
   PubMed Web of Science ®Google Scholar
• Boer H, Proost JH, Nuver J, et al. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol. 2015;26(11):2305–2310.
   PubMed Web of Science ®Google Scholar
• Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006;367(9512):754–765.
   PubMed Web of Science ®Google Scholar
• Cullen M. Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours. Ann Oncol. 2012;23(Suppl 10):x342–8.
   Google Scholar
• Feldman DR. Update in germ cell tumours. Curr Opin Oncol. 2015;27(3):177–184.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Aparicio J, Beyer J, et al. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol. 2015;26(5):833–838.
   PubMed Web of Science ®Google Scholar
• Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24(4):878–888.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Honecker F, Bokemeyer C. Treatment of germ cell tumors–update 2006. Ann Oncol. 2006;17(Suppl 10):x31–5.
   Google Scholar
• Mortensen MS, Lauritsen J, Gundgaard MG, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66(6):1172–1178.
   PubMed Web of Science ®Google Scholar
• Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20(22):4448–4452.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Maroto P, Garcia del Muro X, et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014;25(11):2173–2178.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Germa JR, Garcia del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005;23(34):8717–8723.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29(35):4677–4681.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Fossa SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi125–32.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Roth B, Albers P, et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol. 2013;31(28):3490–3493.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(4):1146.
   PubMed Web of Science ®Google Scholar
• Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200–1208.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513–1523.
   PubMed Web of Science ®Google Scholar
• Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol. 2004;22(4):640–647.
   PubMed Web of Science ®Google Scholar
• Horwich A, Fossa SD, Huddart R, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014;110(1):256–263.
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89(19):1429–1439.
   PubMedGoogle Scholar
• Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957–962.
   PubMed Web of Science ®Google Scholar
• Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293–300.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Garcia del Muro X, Maroto P, et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol. 2003;14(6):867–872.
   PubMed Web of Science ®Google Scholar
• Steiner H, Holtl L, Wirtenberger W, et al. Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology. 2002;60(2):324–328.
   PubMed Web of Science ®Google Scholar
• Reiter WJ, Brodowicz T, Alavi S, et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol. 2001;19(1):101–104.
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Bruggeboes B, Pichlmeier U, et al. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology. 2000;55(1):102–106.
   PubMed Web of Science ®Google Scholar
• Krege S, Kalund G, Otto T, et al. Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol. 1997;31(4):405–407.
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Krain J, Kuster J, et al. Adjuvant carboplatin treatment for seminoma clinical stage I. J Cancer Res Clin Oncol. 1996;122(1):63–66.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Harstrick A, Bokemeyer C, et al. Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer. 1993;72(1):237–243.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Cavallin-Stahl E, Dahl O, et al. Management of clinical stage I seminomatous testicular cancer: a report from SWENOTECA. J Clin Oncol. 2014;32(suppl):abstr 4508.
   Google Scholar
• Steiner H, Scheiber K, Berger AP, et al. Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int. 2011;107(7):1074–1079.
   PubMed Web of Science ®Google Scholar
• Horwich A. Stage I seminoma. Onkologie. 2006;29(12):554–555.
   PubMedGoogle Scholar
• Powles T, Robinson D, Shamash J, et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol. 2008;19(3):443–447.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33(1):51–57.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014;32(34):3817–3823.
   PubMed Web of Science ®Google Scholar
• Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10(11):1762–1768.
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21(8):1505–1512.
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol. 2003;21(22):4092–4099.
   PubMed Web of Science ®Google Scholar
• Lago-Hernandez CA, Feldman H, O’Donnell E, et al. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015;26(7):1396–1401.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Moore C, Chi KN, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol. 2010;21(6):1296–1301.
   PubMed Web of Science ®Google Scholar
• Sturgeon JF, Moore MJ, Kakiashvili DM, et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. Eur Urol. 2011;59(4):556–562.
   PubMed Web of Science ®Google Scholar
• Baniel J, Foster RS, Rowland RG, et al. Complications of primary retroperitoneal lymph-node dissection for low-stage testicular cancer. World J Urol. 1994;12(3):139–142.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol. 2003;169(5):1710–1714.
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966–2972.
   PubMed Web of Science ®Google Scholar
• Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996;14(4):1106–1113.
   PubMed Web of Science ®Google Scholar
• Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol. 1996;14(2):441–448.
   PubMed Web of Science ®Google Scholar
• Chevreau C, Mazerolles C, Soulie M, et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol. 2004;46(2):209–214. discussion 14–5
   PubMed Web of Science ®Google Scholar
• Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27(13):2122–2128.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Stahl O, Hakansson U, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol. 2014;25(11):2167–2172.
   PubMed Web of Science ®Google Scholar
• Chau C, Cathomas R, Wheater M, et al. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience. Ann Oncol. 2015;26(9):1865–1870.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Solberg A, Hakansson U, et al. Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. Acta Oncol (Madr). 2015;54(4):493–499.
   PubMed Web of Science ®Google Scholar
• Ruf CG, Gnoss A, Hartmann M, et al. Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia. Andrology. 2015;3(1):92–98.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7(3):387–391.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005;23(36):9290–9294.
   PubMed Web of Science ®Google Scholar
• Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917–924.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Delva R, Caty A, et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol. 2014;65(2):381–386.
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–1440.
   PubMed Web of Science ®Google Scholar
• De Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer. 1998;78(6):828–832.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16(4):1287–1293.
   PubMed Web of Science ®Google Scholar
• de Wit R, Louwerens M, de Mulder PH, et al. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer J Int Du Cancer. 1999;83(6):831–833.
   PubMed Web of Science ®Google Scholar
• de Wit R, Skoneczna I, Daugaard G, et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol. 2012;30(8):792–799.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Hu J, Dorff TB, et al. Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). J Clin Oncol. 2013;31(suppl):abstr 4501.
   Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25(3):247–256.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22(5):1054–1061.
   PubMed Web of Science ®Google Scholar
• Calabro F, Albers P, Bokemeyer C, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol. 2012;61(6):1212–1221.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15(13):1442–1450.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Kollmannsberger C, Honecker F, et al. Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer. 2008;44(12):1663–1669.
   PubMed Web of Science ®Google Scholar
• International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28(33):4906–4911.
   PubMed Web of Science ®Google Scholar
• Berger LA, Bokemeyer C, Lorch A, et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol. 2014;140(7):1211–1220.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549–6555.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr., Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16(7):2500–2504.
   PubMed Web of Science ®Google Scholar
• Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16(7):1152–1159.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Gravis G, Flechon A, et al. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol. 2014;25(5):987–991.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007;25(1):85–90.
   PubMed Web of Science ®Google Scholar
• Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30(8):800–805.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer–a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7(7):932–939.
   PubMed Web of Science ®Google Scholar
• McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559–2563.
   PubMed Web of Science ®Google Scholar
• Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29(16):2178–2184.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340–348.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28(10):1706–1713.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Huddart R, Hall E, et al. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer. 2011;2:374–377.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22(1):108–114.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol. 2008;19(3):448–453.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol. 2011;22(12):2654–2660.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy MJ, Feldman DR, Carver BS, et al. Late Relapse of Testicular Germ Cell Tumors. Urol Clin North Am. 2015;42(3):359–368.
   PubMed Web of Science ®Google Scholar
• Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996;14(10):2638–2645.
   PubMed Web of Science ®Google Scholar
• Veenstra CM, Vaughn DJ. Third-line chemotherapy and novel agents for metastatic germ cell tumors. Hematol Oncol Clin North Am. 2011;25(3):577–591. ix
   PubMed Web of Science ®Google Scholar
• O’Carrigan B, Grimison P. Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. Urol Oncol. 2015;33(8):343–354.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Tu SM, Bassett R, et al. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015;26(10):2125–2132.
   PubMed Web of Science ®Google Scholar
• Nitzsche B, Gloesenkamp C, Schrader M, et al. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer. 2012;107(11):1853–1863.
   PubMed Web of Science ®Google Scholar
• Necchi A, Nicolai N, Piva L, et al. Long-term results of a combination of paclitaxel, oxaliplatin and gemcitabine as far rescue in heavily pre-treated male germ cell tumors (GCT). J Clin Oncol. 2008;26(suppl):abstr 16036.
   Google Scholar
• Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004;15(3):493–497.
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Rosti G, Aieta M, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol. 2006;50(5):1032–1038. discussion 38–9
   PubMed Web of Science ®Google Scholar
• Sadeghi S, Quinn D, Tsao-Wei D, et al. Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): Final results. J Clin Oncol. 2013;31(suppl):abstr 4531.
   Google Scholar
• Oechsle K, Kollmannsberger C, Honecker F, et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol. 2011;60(4):850–855.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007;25(5):513–516.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol. 2004;46(2):216–221.
   PubMed Web of Science ®Google Scholar
• Shamash J, Powles T, Mutsvangwa K, et al. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol. 2007;18(5):925–930.
   PubMed Web of Science ®Google Scholar
• Chieffi P, Chieffi S. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: an overview. J Cell Physiol. 2013;228(8):1641–1646.
   PubMed Web of Science ®Google Scholar
• Juliachs M, Munoz C, Moutinho CA, et al. The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res. 2014;20(3):658–667.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Shirahama T, Imazono Y, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer. 1999;85(6):1323–1330.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010;28(4):523–528.
   PubMed Web of Science ®Google Scholar
• Skoneczna IA, Natorska U, Tacikowska M, et al. Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study. J Clin Oncol. 2014;32(suppl4):abstr 367.
   Google Scholar
• Giannatempo P, Nicolai N, Farè E, et al. Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial. J Clin Oncol. 2014;32(suppl 4):abstr 376.
   Google Scholar
• Einhorn LH, Brames MJ, Heinrich MC, et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol. 2006;29(1):12–13.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Einhorn LH, Quinn DI, et al. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013;31(4):1016–1022.
   PubMed Web of Science ®Google Scholar
• Rick O, Braun T, Siegert W, et al. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer. 2006;42(12):1775–1779.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Bokemeyer C, Honecker F. Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol. 2010;136(1):165–167.
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33.
   PubMed Web of Science ®Google Scholar
• Frankhauser CD, Fontecedro AC, Beyer J, et al. Frequent expression of PD-L1 in testicular germ cell tumors. J Clin Oncol. 2015;33(suppl 7):abstr 379.
   Google Scholar
• Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA. 2015;112(6):1839–1844.
   PubMed Web of Science ®Google Scholar
• Jain A, Brames MJ, Vaughn D. et al. Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT). J Clin Oncol. 2011;29(suppl):abstr 4579.
   Google Scholar